Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 5/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | CCR3 | P51677 | 3/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL921407 | 0.84 | KCNH2 (0.44) | KCNH2SIGMAR1 | |
| SCHEMBL921511 | 0.84 | KCNH2 (0.41) | KCNH2L3MBTL1SSTR4SIGMAR1CCR3 | |
| SCHEMBL921167 | 0.84 | KCNH2 (0.46) | KCNH2L3MBTL1 | |
| SCHEMBL923158 | 0.83 | KCNH2 (0.47) | KCNH2 | |
| SCHEMBL705682 | 0.83 | KCNH2 (0.38) | KCNH2 | |
| SCHEMBL924650 | 0.82 | KCNH2 (0.52) | KCNH2 | |
| SCHEMBL703858 | 0.80 | KCNH2 (0.33) | KCNH2 | |
| SCHEMBL4300038 | 0.78 | KCNH2 (0.46) | KCNH2 | |
| SCHEMBL2686089 | 0.78 | KCNH2 (0.61) | KCNH2 | |
| SCHEMBL9957784 | 0.77 | KDM4E (0.52) | KCNH2MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108577-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2012-05-03 | — | — | US | disclosed |
| US-7875715-B2 | 6-[({1-[2-(7-methoxy-2-oxoquinoxalin-1(2H)-yl)ethyl]piperidin-4-yl}amino)methyl]-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one; antibacteria; methicillin-resistant Staphylococcus aureus (MRSA), methicillin-resistant coagulase-negative staphylococci (MRCNS), penicillin-resistant Streptococcus pneumoniae | ASTRAZENECA AB (SE) | 2011-01-25 | — | — | US | disclosed |
| US-20100152441-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108577-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | PIGS, BPGM, IPMK | KCNH2 4242/4885L3MBTL1 1630/4885SSTR4 4829/4885 |
| US-20100152441-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | PIGS, BPGM, IPMK | KCNH2 4242/4885L3MBTL1 1630/4885SSTR4 4829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.